Head-to-head evidence
AZD6234 vs GUB-UCN2
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: Amylin receptor · full Obesity pipeline
AZD6234
Developed by AstraZeneca
NCT06595238 · Phase 2 · completed
Randomized, quadruple-blind, placebo-controlled Phase 2 trial in 262 participants with obesity or overweight; primary endpoint Percent change in body weight from baseline to week 26. Completed December 2025; numerical results not yet posted to the registry, so the grade is the design ceiling for a completed controlled study without results.
Next expected readout: October 2026 · NCT07017179 (registry estimate)
GUB-UCN2
Developed by Gubra
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2028 · NCT07702890 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AZD6234's landscape · GUB-UCN2's landscape